- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01324830
Monotherapy Dose Finding With BI 847325 in Solid Tumours
An Open Label Phase Ia/Ib Study of Two Dosing Schedules of BI 847325, Orally Administered Once a Day in Patients With Advanced Solid Tumours, With Repeated Cyclic Administration in Patients With Clinical Benefit
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Bruxelles, Belgien
- 1287.1.3201 Boehringer Ingelheim Investigational Site
-
Leuven, Belgien
- 1287.1.3202 Boehringer Ingelheim Investigational Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion criteria:
- Patients with a histologically or cytologically confirmed diagnosis of an advanced unresectable and/or metastatic solid tumour, and who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not amenable to standard therapies.
- Age 18 years and older
- Written informed consent consistent with International conference on harmonization - Good clinical practice (ICH-GCP) and local legislation
- Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
- Recovery of therapy-related toxicities from previous anti-tumour therapies to Common Terminology Criteria for Adverse Events (CTCAE) = grade 1 (with the exception of alopecia).
- Written informed consent to the use of archival tumour sample for determination of the BRAF/Tat sarcoma viral oncogene homolog (RAS) mutational status.
- Life expectancy of at least 12 weeks.
In escalation phase, when pharmacokinetic (PK) close to predicted Cmax or when signs of progressive disease (PD) modulation present, optional tumour biopsies (at same timepoints as in expansion phase) for the patients who consented to it.
In addition, all patients included in the expansion phase (part Ib) must:
- have been diagnosed with one of the following tumours: melanoma, colorectal carcinoma, Non Small Cell Lung Cancer (NSCLC) or exocrine pancreas adenocarcinoma, and have been shown on their archival tumour sample to have KRAS or BRAF mutation.
- have a measurable disease.
- have documented/proven progressive disease within the last 6 months, according to Response Evaluation Criteria In Solid Tumours (RECIST) criteria
11. have a tumour lesion accessible for biopsies (pre- and post-treatment): this is mandatory for patients with colorectal carcinoma or melanoma, optional for patients with NSCLC or exocrine pancreas adenocarcinoma.
Exclusion criteria:
- Inability to swallow tablets.
- Additional other serious illness , concomitant non-oncological disease (e.g. active infectious disease or known chronic Hepatitis B/Hepatitis C infection and HIV), or ongoing toxicity from prior therapies considered by the investigator to potentially compromise patient's safety in this trial.
- Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the last 28 days.
- Second malignancy currently requiring another anti-cancer therapy.
- Absolute neutrophil count less than 1500/mm3.
- Platelet count less than 100 000/mm3.
- Bilirubin greater than 1.5 mg/dL (>26 µmol/L, Système international (SI) unit equivalent) (except known Gilbert's syndrome).
- Aspartate amino transferase (AST) and/or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (if related to liver metastases, greater than five times the upper limit of normal).
- Serum creatinine greater than 1.5 mg/dL (>132 µmol/L, SI unit equivalent).
- Previous episode of QT prolongation due to a medication which, as a result of it, had to be discontinued; or long QT syndrome; or corrected QT interval (QTc) with Fridericia's correction >480 msec on screening ECG.
- Pregnancy or breastfeeding.
- Women or men who are sexually active and unwilling to use a medically acceptable method of contraception.
- Treatment with other investigational drugs or participation in another clinical interventional trial within the past four weeks before start of therapy or concomitant with this trial.
- Systemic anti-cancer therapy or radiotherapy within the past four weeks before start of therapy or concomitantly with this trial. This restriction does not apply to Luteinizing hormone-releasing hormone (LHRH) agonists, steroids and bisphosphonates.
- Patients unable to comply with the protocol.
- Active alcohol or drug abuse.
- history or presence of cardiovascular abnormalities deemed clinically relevant by the investigator. Myocardial infarction within 6 months prior to study.
- Cardiac left ventricular ejection fraction <50% or less than institutional lower limit of normal by Multiple Gated Acquisition scan (MUGA) or echocardiography
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: arm A
14 days once a day oral intake of BI 847325 followed by 7 days break in 3-week cycles
|
low to high dose
|
Eksperimentel: arm B
5 days once daily oral intake of BI 847325 followed by 2 days break, repeated every week
|
low to high dose
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Percentage of Patients With Dose Limiting Toxicity During the First Treatment Cycle in Phase Ia Part of the Study
Tidsramme: 3 weeks
|
Occurrence of dose limiting toxicity (DLT) during the first treatment cycle for the treatment Schedules A and B. Some patients excluded from Treated Set (TS) as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients. |
3 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Best Overall Response
Tidsramme: From the start of treatment until the last evaluable assessment. The data cut-off date is 29-Nov-2013
|
Best overall response was the best response a patient experienced during their time on study from the start of treatment until: disease progression, the last evaluable assessment in the absence of progression, or the start of subsequent anti-cancer therapy.
Death was not considered as progressive disease when determining best overall response; patients who died prior to an evaluable imaging assessment were reported as not evaluable.
Some patients were excluded from TS as they were not evaluable for determination of maximum tolerated dose.
Thus the number of evaluable TS patients are not the same as the number of original TS patients.
|
From the start of treatment until the last evaluable assessment. The data cut-off date is 29-Nov-2013
|
Objective Response
Tidsramme: From the start of treatment and the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.
|
Objective response was a best overall response of complete or partial response, recorded between the start of treatment and the earliest of disease progression, death, or the end of treatment. Some patients excluded from TS as they were not evaluable for determination of maximum tolerated dose. Thus the number of evaluable TS patients are not the same as the number of original TS patients. |
From the start of treatment and the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.
|
Disease Control
Tidsramme: From the start of treatment to the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.
|
Disease control was a best overall response of complete response, partial response or stable disease, recorded between the start of treatment and the earliest of disease progression, death, or the end of treatment.
Some patients excluded from TS as they were not evaluable for determination of maximum tolerated dose.
Thus the number of evaluable TS patients are not the same as the number of original TS patients.
|
From the start of treatment to the earliest of disease progression, death, or the end of treatment. The data cut-off date is 29-Nov-2013.
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- 1287.1
- 2010-023832-18 (EudraCT nummer: EudraCT)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Neoplasmer
-
Guangzhou First People's HospitalAfsluttet
Kliniske forsøg med day 1 to day 14
-
Johnson & Johnson Vision Care, Inc.AfsluttetSynsstyrkeForenede Stater
-
Johnson & Johnson Vision Care, Inc.AfsluttetØjenfysiologiForenede Stater
-
Queen's UniversityAfsluttetBorderline personlighedsforstyrrelse | SpiseforstyrrelserCanada
-
AshtaYoga, LLCColumbia University; University Of Nigeria Teaching Hospital; Project PINKBLUE... og andre samarbejdspartnereIkke rekrutterer endnu
-
Zhongshan Ophthalmic Center, Sun Yat-sen UniversityRekruttering
-
Johnson & Johnson Vision Care, Inc.Afsluttet
-
Massachusetts General HospitalAmerican Cancer Society, Inc.Afsluttet
-
Coopervision, Inc.Afsluttet
-
University of HoustonAfsluttetLågsvisker epiteliopatiForenede Stater
-
Johnson & Johnson Vision Care, Inc.Afsluttet